Try to walk or bike to work if you can. Avoid or limit alcohol and caffeine consumption. Manage excessive fatigue, irritability, lack of concentration or panic. Take a moment to inhale slowly before entering a work area or entering or exiting a patient space. cancer patients. Strategy The review included two phases: 1) search and systematic revision of the medical literature; 2) consensus and revision of the document drafted by national scientific societies involved in the management and care of malignancy individuals using the revised Delphi method. The final results were offered at a videoconference with all the participants. Also, additional comment and recommendations were discussed. The final document was revised and authorized for publication from the users of the panel. Results The consensus panel included 18 associates from medical societies from Argentina who assessed the evidence and then made recommendations for the management of malignancy patients in our country. International recommendations (CDC; Rabbit Polyclonal to API-5 ASCO, NCCN and ESMO) were considered as a background for analysis, as well as institutional recommendations and an open survey given to 114 healthcare professionals from your scientific societies involved in this study. The recommendations are grouped as follows: 1) general care interventionstraining of the personnel, cleaning and disinfection of the hospital premises and individual scheduling; 2) treatment decisionspatient care, surgeries, immunosuppressive therapy, radiotherapy and screening; 3) honest considerationsoptimisation of resources, end-of-life care for critically-ill individuals; 4) management of hospitalised individuals; and 5) wellbeing of the healthcare team. The general recommendation arising from the study is that the management of malignancy patients must adapt to the excellent pandemic status quo without disregarding treatment or treatment options. Moreover, healthcare professional accompaniment of all individuals should not be neglected. All healthcare experts must make a significant joint effort to produce multidisciplinary teams to discuss the most appropriate measures for each particular scenario. Conclusions The medical evidence available on this topic worldwide is in progress. This together with the epidemiologically shifting scenario poses unprecedented difficulties in the management of malignancy amidst this global pandemic. Furthermore, the key role of GZD824 the healthcare structural organisation appears evident, such as the drafting of obvious guidelines for all the stakeholders, adaptability to constant switch and an interdisciplinary shared vision through consensus to provide adequate care to our cancer individuals in the light of uncertainty and fast-paced switch. [2], these 18 individuals represent a heterogeneous group and are not an ideal representation of the entire population of malignancy patients. Another recent publication, based on instances of malignancy and COVID-19 from three private hospitals in Wuhan, reports results from 28 individuals. In these cases, 53.6% developed severe forms of the illness and 28.6% were related deaths [18]. Surgeries Can surgeries become cancelled or delayed? The CDC suggests elective surgeries are rescheduled if GZD824 possible. The American College of Cosmetic surgeons has also given a recommendation. However, doctors and individuals should discuss individual GZD824 instances, evaluating the potential harm of delaying malignancy related surgeries; without which they risk missing the window of opportunity for surgical treatment of the patient. In many cases, these surgeries cannot be considered as elective [19]. Immunosuppressive therapy Can immunosuppressive therapy become cancelled, delayed or interrupted? Treatment plan For patients having a fever or additional symptoms of illness, a detailed evaluation should be carried out relating to typical medical practice. For individuals with COVID-19 who are currently receiving treatment for malignancy, consider delaying or changing the malignancy treatment for individuals with active illness. The current info suggests that malignancy patients are at a higher risk of illness and complications from COVID-19 than additional patients. For individuals with no known COVID-19 illness, in the majority of instances, it is likely to be more important to start or continue systematic tumor treatment, than delay or interrupt it over issues about possible COVID-19 illness. However, decisions should be made on an individual basis after considering the overall objectives of treatment, the current oncological state of the.